Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glycopyrronium bromide + formoterol
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
TQC3927 is an inhaled fixed-dose combination therapy under development by Chia Tai Tianqing Pharmaceutical Group (a subsidiary of Sino Biopharmaceutical) for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It consists of glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA), and formoterol fumarate, a long-acting beta-2 adrenergic agonist (LABA). The combination provides dual bronchodilation by targeting two distinct pathways: glycopyrronium inhibits M3 muscarinic receptors in the airway smooth muscle to prevent bronchoconstriction, while formoterol stimulates beta-2 adrenoceptors to induce muscle relaxation. This synergistic approach aims to improve lung function and alleviate symptoms in patients with COPD. The drug is administered via a dry powder inhaler (DPI) and is currently being evaluated in Phase II clinical trials.
- Brand names
- Bevespi AerosphereBevespi
- Other names
- glyceryl bromide + formoterolglycopyrronium bromide + formoterol fumarate
02
Targets
M1 (Muscarinic acetylcholine receptor M1)CHRM3 (M3)ADRB2 (β2)ADRB1 (β1)CHRM5 (M5)CHRM2 (M2)ADRB3 (β3)CHRM4 (M4)
Beyond the preview
Go deeper on glycopyrronium bromide + formoterol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glycopyrronium bromide + formoterol.